Description
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Catalog No.
DHD37502
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P20138
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
Note
For research use only. Not suitable for clinical or therapeutic use.
關(guān)鍵字： Lintuzumab;DHD37502;gp67, SIGLEC3;
武漢佰樂博生物（Biolab Reagents）由五位畢業(yè)于華中科技大學(xué)，華中農(nóng)業(yè)大學(xué)，武漢大學(xué)等知名高校，且具有二十年工作經(jīng)驗(yàn)的生命科學(xué)領(lǐng)域頂級(jí)研究者創(chuàng)立于2021年，憑借豐富的產(chǎn)品開發(fā)經(jīng)驗(yàn)，利用全球領(lǐng)先的技術(shù)平臺(tái)，引進(jìn)和整合全球高品質(zhì)的蛋白、抗體和試劑盒產(chǎn)品。目前，佰樂博生物作為法國AntibodySystem和ProteoGenix在亞洲的獨(dú)家總代理，提供近30,000種生命科學(xué)試劑，核心產(chǎn)品涵蓋蛋白、抗體和試劑盒，旨在為科研工作者提供專業(yè)、全面、可靠的試劑支持，推動(dòng)生命科學(xué)研究的深入發(fā)展。